Furthermore, IDO has been shown to negatively impact efficacy of immune-based therapies such as of T-cells carrying chimeric antigen receptors [15] while high kynurenine concentrations predict an unfavorable outcome in AML patients [16]. The gene discussed is IDO1; the disease is acute myeloid leukemia.